Lantern Pharma Inc. 8K

Lantern Pharma furnished Q2 2026 financial results and a business update, including the spin-out of Open Medicine AI as a separate subsidiary, key clinical and regulatory milestones for LP-300 and LP-184, a new LP-184 biomarker patent allowance, and detailed operating and warrant-driven financial results.

Lantern Pharma Inc. filed a Form 8-K to furnish its second quarter 2026 financial results and a comprehensive business update, highlighting the establishment of Open Medicine AI (OMAI) as a wholly owned subsidiary with board-approved commercial licensing agreements for its multi-agent AI drug discovery platform, continued clinical progress in its oncology pipeline including deepening progression-free survival benefit and FDA-cleared protocol amendments for the LP-300 HARMONIC Phase 2 NSCLC trial, EMA clearance for an investigator-initiated biomarker-selected Phase 1b/2 bladder cancer trial of LP-184 (zirdafulven), FDA clearance to initiate a Phase 1b/2 LP-184 trial in triple-negative breast cancer, a new USPTO Notice of Allowance covering a three-gene expression signature for LP-184 patient selection, and financial metrics showing approximately $7.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026, a 25% year-over-year reduction in loss from operations to about $3.5 million for Q2 2026, but a higher net loss of about $7.1 million driven largely by non-cash warrant-related expense tied to stock price appreciation.

Filing Facts

CIK

1763950

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-037979

Alert Tier

6